Reality Check on Non-Small Cell Lung Cancer ALK+ or ROS1+
Market access for Non-small cell lung cancer ALK+ or ROS1+ treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.
To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:
- Payer Insights: Under the pharmacy benefit, about 75% of the lives under commercial formularies are covered with utilization management restrictions
- Class Trends: In May 2020, the FDA expanded the label of Takeda Pharmaceutical Company Limited’s Alunbrig (brigatinib) to include the treatment of newly diagnosed adults with anaplastic lymphoma kinase-positive NSCLC as detected by an FDA-approved test
- Key Findings: Competition is growing, with six different drugs from four different manufacturers targeting these gene mutations in patients with NSCLC
What can pharma do to curb this trend and overcome these challenges?
Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.
Download the full Reality Check now.